About DopaFuse

  • Designed for Parkinson's Disease patients
  • Provides continuous delivery of levodopa
  • May provide more stable drug levels in the blood, potentially reducing "Off" time
  • Uses the OraFuse platform

About OraFuse®

  • OraFuse is SynAgile's proprietary technology for continuous drug delivery in the mouth
  • Can be used for numerous drugs

The OraFuse Technology: A novel, non-invasive method of drug delivery in the mouth

Drug Types

Orally-delivered drugs, including:

Narrow therapeutic index drugs.
Drugs that cannot be formulated for extended release



Buccally-delivered drugs



Topical drugs for the mouth, pharynx, and esophagus

Benefits



More stable plasma drug concentrations.Fewer dose-related side effects.

Allows buccal delivery of drugs requiring frequent or continuous dosing, rather than just drugs requiring episodic dosing.

Allows topical delivery of drugs requiring frequent or continuous dosing to the mouth, pharynx and esophagus.

Founders

SynAgile was founded by highly successful serial inventor-entrepreneurs Adam Heller (CSO) and Ephraim Heller (CEO). The father-son team have over 300 patents (most in use) and a track record which includes the founding of AngioScore (sold for $235 million) and TheraSense (which went public and was later sold for $1.2 billion). Adam Heller is also a coinventor of the first commercialized lithium thionyl chloride battery and a recipient of the US National Medal of Technology and Innovation, the highest technology honor in the United States.

The SynAgile founding team began developing OraFuse after seeing an opportunity to improve patients’ quality of life via a new class of drug delivery devices.

News

SynAgile Corporation Announces Closing of $10.4M of Financing

August 24th, 2017

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse® technology platform, today announced the closing of a $10.4 million round of equity investment.

Read More

83-year-old invents Parkinson's "Retainer" to deliver Oral Levodopa

March 2nd, 2017

“I would love to see the device widely used by people, while I’m still alive,” says Dr Adam Heller. The 83-year-old research professor at the University of Texas, US, who has more than 260 US patents...

Read More

SynAgile Corporation Announces Positive Phase 2A Results

October 8th, 2015

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse® intraoral technology platform, today announced positive results from a proof-of-concept...

Read More
Federal law limits the use of DopaFuse to Investigational Use Only. DopaFuse is not available for sale.